Pancreatic Cancer Research

ResearcherShanghai Jiao Tong UniversityNo recent work listed

Xinzhe Yu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3619-5594; OpenAlex author ID A5034512250. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2015: 2 papers · 2016: 1 paper · 2017: 3 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: none · 2022: none · 2023: 1 paper

Papers 8

  1. hENT1's role in adjuvant intra-arterial gemcitabine-based chemotherapy for resectable pancreatic cancer patients. First author DOI 10.1186/s12876-023-02666-x↗
  2. Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression. Co-author DOI 10.2147/ijn.s166769↗
  3. Dose surgical resection of hepatic metastases bring benefits to pancreatic ductal adenocarcinoma? A systematic review and meta-analysis. Co-author DOI 10.1016/j.ijsu.2017.10.066↗
  4. The relationship between SPARC expression in primary tumor and metastatic lymph node of resected pancreatic cancer patients and patients' survival. Co-author DOI 10.1016/s1499-3872(16)60168-6↗
  5. Triple-functional albumin-based nanoparticles for combined chemotherapy and photodynamic therapy of pancreatic cancer with lymphatic metastases. Co-author DOI 10.2147/ijn.s131295↗
  6. Application of Deuteporfin in the Metastatic Lymph Node Mapping of Pancreatic Cancer: An in vivo Study. Co-author DOI 10.1111/php.12574↗
  7. An in vitro and in vivo study of gemcitabine-loaded albumin nanoparticles in a pancreatic cancer cell line. Co-author DOI 10.2147/ijn.s93835↗
  8. Characterization of the role of the photosensitizer, deuteporfin, in the detection of lymphatic metastases in a pancreatic cancer xenograft model. Co-author DOI 10.3892/ol.2015.3441↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chen Jin · 8 shared papers, 2015–2023 · strength 0.73
  2. Hengchao Li · 4 shared papers, 2015–2023 · strength 0.40
  3. Deliang Fu · 5 shared papers, 2015–2017 · strength 0.37
  4. Di Yang · 5 shared papers, 2015–2018 · strength 0.34
  5. Zhongyi Guo · 3 shared papers, 2017–2018 · strength 0.24
  6. Xinyu Huang · 1 shared paper, 2023 · strength 0.22
  7. Wei Wang · 1 shared paper, 2023 · strength 0.22
  8. Jichun Gu · 2 shared papers, 2017 · strength 0.17
  9. Lie Yao · 2 shared papers, 2016–2018 · strength 0.15
  10. Hang He · 2 shared papers, 2015–2016 · strength 0.11
  11. Feng Wang · 1 shared paper, 2018 · strength 0.09
  12. Deliang Fu · 1 shared paper, 2018 · strength 0.09
  13. Feng Yang · 1 shared paper, 2017 · strength 0.08
  14. Ji Li · 1 shared paper, 2015 · strength 0.06
  15. Ji Li · 1 shared paper, 2016 · strength 0.06
  16. Deliang Fu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.